June 16 (Reuters) - Supernus Pharmaceuticals Inc ( SUPN )

:

* SUPERNUS PHARMACEUTICALS TO ACQUIRE SAGE THERAPEUTICS,

STRENGTHENING ITS NEUROPSYCHIATRY PRODUCT PORTFOLIO

* UPFRONT CASH PAYMENT OF $8.50 PER SHARE

* EXPECTED TO BE SIGNIFICANTLY ACCRETIVE IN 2026 WITH

POTENTIAL

COST SYNERGIES OF UP TO $200 MILLION ON AN ANNUAL BASIS

* DEALFOR AN AGGREGATE OF UP TO APPROXIMATELY $795 MILLION

OR

$12.00 PER SHARE

Source text:

Further company coverage: